{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:32:17Z","timestamp":1792654337088,"version":"4.5.0"},"reference-count":106,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T00:00:00Z","timestamp":1519344000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NHRI-EX105-10334EI"],"award-info":[{"award-number":["NHRI-EX105-10334EI"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 106-2628-E-038-001-MY3"],"award-info":[{"award-number":["MOST 106-2628-E-038-001-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2018.00033","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T04:22:11Z","timestamp":1519359731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":68,"title":["Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products"],"prefix":"10.3389","volume":"5","author":[{"given":"Victor J.","family":"Drew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Li","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Burnouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archophthalmol.2009.103","article-title":"Prevalence of dry eye disease among US men: estimates from the physicians\u2019 health studies","volume":"127","author":"Schaumberg","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jtos.2016.04.005","article-title":"Understanding symptoms and quality of life in patients with dry eye syndrome","volume":"14","author":"Barabino","year":"2016","journal-title":"Ocul Surf"},{"key":"B3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00003226-199907000-00003","article-title":"Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye","volume":"18","author":"Shimmura","year":"1999","journal-title":"Cornea"},{"key":"B4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0002-9394(03)00218-6","article-title":"Prevalence of dry eye syndrome among US women","volume":"136","author":"Schaumberg","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0002-9394(14)71688-5","article-title":"Prevalence of dry eye among the elderly","volume":"124","author":"Schein","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/00003226-200009000-00009","article-title":"The diagnosis and management of dry eye: a twenty-five-year review","volume":"19","author":"Pflugfelder","year":"2000","journal-title":"Cornea"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3238\/arztebl.2015.0071","article-title":"The pathophysiology, diagnosis, and treatment of dry eye disease","volume":"112","author":"Messmer","year":"2015","journal-title":"Dtsch Arztebl Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/13543784.2016.1249564","article-title":"Investigational drugs in dry eye disease","volume":"25","author":"Nebbioso","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archopht.124.9.1286","article-title":"Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions","volume":"124","author":"Sullivan","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1167\/iovs.07-0002","article-title":"Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL\/6 mice: effects of desiccating stress","volume":"48","author":"Yoon","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.advms.2017.03.003","article-title":"Pro-inflammatory cytokines associated with clinical severity of dry eye disease of patients with depression","volume":"62","author":"Mrugacz","year":"2017","journal-title":"Adv Med Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0173301","DOI":"10.1371\/journal.pone.0173301","article-title":"Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1167\/iovs.03-1145","article-title":"Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface","volume":"45","author":"Luo","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/eye.2014.38","article-title":"Analysis of Th17-associated cytokines in tears of patients with dry eye syndrome","volume":"28","author":"Tan","year":"2014","journal-title":"Eye (Lond)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1038\/srep22480","article-title":"Sleep and mood disorders in dry eye disease and allied irritating ocular diseases","volume":"6","author":"Ayaki","year":"2016","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"46453","DOI":"10.1038\/srep46453","article-title":"The prevalence of depression and depressive symptoms among eye disease patients: a systematic review and meta-analysis","volume":"7","author":"Zheng","year":"2017","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/eye.2016.186","article-title":"Depression and anxiety in dry eye disease: a systematic review and meta-analysis","volume":"30","author":"Wan","year":"2016","journal-title":"Eye (Lond)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0123299","DOI":"10.1371\/journal.pone.0123299","article-title":"Associations between subjective happiness and dry eye disease: a new perspective from the Osaka study","volume":"10","author":"Kawashima","year":"2015","journal-title":"PLoS One"},{"key":"B20","first-page":"111","article-title":"Dry eye disease in patients treated with antidepressants","volume":"115","author":"Mrugacz","year":"2013","journal-title":"Klin Oczna"},{"key":"B21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and humanistic burden of dry eye disease in Europe, North America, and Asia: a systematic literature review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul Surf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/ICO.0b013e3181f7f363","article-title":"The economic burden of dry eye disease in the United States: a decision tree analysis","volume":"30","author":"Yu","year":"2011","journal-title":"Cornea"},{"key":"B23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/OPTH.S30625","article-title":"Annual direct cost of dry eye in Japan","volume":"6","author":"Mizuno","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/09286580600801044","article-title":"The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists","volume":"13","author":"Clegg","year":"2006","journal-title":"Ophthalmic Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1097\/OPX.0000000000000965","article-title":"Measurement of symptoms pre- and post-treatment of dry eye syndromes","volume":"93","author":"McMonnies","year":"2016","journal-title":"Optom Vis Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD009327","DOI":"10.1002\/14651858.CD009327.pub2","article-title":"Autologous serum eye drops for dry eye","volume":"8","author":"Pan","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD009729","DOI":"10.1002\/14651858.CD009729.pub2","article-title":"Over the counter (OTC) artificial tear drops for dry eye syndrome","volume":"2","author":"Pucker","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/OPTH.S78184","article-title":"Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial","volume":"9","author":"Simmons","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2147\/OPTH.S81355","article-title":"Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution","volume":"9","author":"Fernandez","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/TCRM.S77091","article-title":"A randomized crossover study comparing trehalose\/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome","volume":"11","author":"Pinto-Bonilla","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5301\/ejo.5000836","article-title":"A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome","volume":"27","author":"Chiambaretta","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1537-2995.2008.01665.x","article-title":"Autologous serum eyedrops: literature review and implications for transfusion medicine specialists","volume":"48","author":"Yamada","year":"2008","journal-title":"Transfusion"},{"key":"B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00004397-200010000-00009","article-title":"Serum application for the treatment of ocular surface disorders","volume":"40","author":"Tsubota","year":"2000","journal-title":"Int Ophthalmol Clin"},{"key":"B34","first-page":"9","article-title":"Use of autologous serum in ophthalmic practice","volume":"82","author":"Lopez-Garcia","year":"2007","journal-title":"Arch Soc Esp Oftalmol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clae.2015.01.007","article-title":"Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye","volume":"38","author":"Bhargava","year":"2015","journal-title":"Cont Lens Anterior Eye"},{"key":"B37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10787-016-0291-2","article-title":"Proper balance of omega-3 and omega-6 fatty acid supplements with topical cyclosporine attenuated contact lens-related dry eye syndrome","volume":"24","author":"Wang","year":"2016","journal-title":"Inflammopharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jtos.2016.01.001","article-title":"Lifitegrast, a novel integrin antagonist for treatment of dry eye disease","volume":"14","author":"Perez","year":"2016","journal-title":"Ocul Surf"},{"key":"B39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ACI.0000000000000309","article-title":"Emerging therapeutics for ocular surface disease","volume":"16","author":"Bielory","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2017.1341988","article-title":"The use of topical corticosteroids for treatment of dry eye syndrome","author":"Cutolo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0157982","DOI":"10.1371\/journal.pone.0157982","article-title":"Synergistic effect of artificial tears containing epigallocatechin gallate and hyaluronic acid for the treatment of rabbits with dry eye syndrome","volume":"11","author":"Tseng","year":"2016","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jtos.2014.12.006","article-title":"Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis","volume":"13","author":"Wan","year":"2015","journal-title":"Ocul Surf"},{"key":"B45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.drudis.2016.04.002","article-title":"Modern approaches to the ocular delivery of cyclosporine A","volume":"21","author":"Agarwal","year":"2016","journal-title":"Drug Discov Today"},{"key":"B46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ophtha.2006.05.077","article-title":"Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment","volume":"114","author":"Wilson","year":"2007","journal-title":"Ophthalmology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/01676830.2011.648802","article-title":"A review of the complications of lacrimal occlusion with punctal and canalicular plugs","volume":"31","author":"Bourkiza","year":"2012","journal-title":"Orbit"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0149-2918(01)80136-3","article-title":"Prevalence of treated dry eye disease in a managed care population","volume":"23","author":"Yazdani","year":"2001","journal-title":"Clin Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1001\/archopht.117.3.389","article-title":"Punctal occlusion","volume":"117","author":"Cohen","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/ICO.0b013e318074e460","article-title":"Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye","volume":"26","author":"Roberts","year":"2007","journal-title":"Cornea"},{"key":"B52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jtos.2015.12.004","article-title":"Effects of punctal occlusion on clinical signs and symptoms and on tear cytokine levels in patients with dry eye","volume":"14","author":"Tong","year":"2016","journal-title":"Ocul Surf"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/bjo.86.9.1031","article-title":"Surgical punctal occlusion: a prospective study","volume":"86","author":"Liu","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"CD006775","DOI":"10.1002\/14651858.CD006775.pub3","article-title":"Punctal occlusion for dry eye syndrome","volume":"6","author":"Ervin","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.blre.2013.02.001","article-title":"Blood-derived biomaterials and platelet growth factors in regenerative medicine","volume":"27","author":"Burnouf","year":"2013","journal-title":"Blood Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.biomaterials.2015.10.065","article-title":"Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?","volume":"76","author":"Burnouf","year":"2016","journal-title":"Biomaterials"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1537-2995.2012.03668.x","article-title":"Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent\/detergent-treated PLT lysate biomaterials against wound bacteria","volume":"53","author":"Burnouf","year":"2013","journal-title":"Transfusion"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ICO.0000000000000271","article-title":"Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease","volume":"33","author":"Hussain","year":"2014","journal-title":"Cornea"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e605","DOI":"10.1111\/aos.12710","article-title":"Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies","volume":"93","author":"Anitua","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1542-0124(12)70613-4","article-title":"Growth factors in the tear film: role in tissue maintenance, wound healing, and ocular pathology","volume":"5","author":"Klenkler","year":"2007","journal-title":"Ocul Surf"},{"key":"B62","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/bjo.83.4.390","article-title":"Treatment of dry eye by autologous serum application in Sj\u00f6gren\u2019s syndrome","volume":"83","author":"Tsubota","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"B63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1755-3768.1992.tb02169.x","article-title":"Epidermal growth factor (EGF) in ocular fluids: presence, origin and therapeutical considerations","volume":"202","author":"Setten","year":"1992","journal-title":"Acta Ophthalmol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2741\/4613","article-title":"The biology of the platelet with special reference to inflammation, wound healing and immunity","volume":"23","author":"Nurden","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B65","first-page":"3532","article-title":"Platelets and wound healing","volume":"13","author":"Nurden","year":"2008","journal-title":"Front Biosci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/IMCRJ.S97297","article-title":"The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center","volume":"9","author":"von Hofsten","year":"2016","journal-title":"Int Med Case Rep J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/vox.12502","article-title":"Serum eye drops: a survey of international production methods","volume":"112","author":"Marks","year":"2017","journal-title":"Vox Sang"},{"key":"B68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.transci.2015.05.014","article-title":"Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: some methodological aspects and clinical considerations","volume":"53","author":"Espinosa","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/aos.12386","article-title":"Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy","volume":"92","author":"Harritshoj","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/bjophthalmol-2012-301668","article-title":"Allogeneic serum eye drops: time these became the norm?","volume":"96","author":"Badami","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3109\/02713683.2012.720340","article-title":"Comparison of autologous serum eye drops with different diluents","volume":"38","author":"Cho","year":"2013","journal-title":"Curr Eye Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"CD009327","DOI":"10.1002\/14651858.CD009327.pub3","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1111\/aos.12167","article-title":"Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study","volume":"92","author":"Lopez-Garcia","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"B74","volume-title":"Recommendations for the Production, Quality Control and Regulation of Plasma for Fractionation","year":"2005"},{"key":"B75","first-page":"148","article-title":"WHO guidelines on good manufacturing practices for blood establishments","volume":"961","year":"2011","journal-title":"WHO Tech Rep Ser"},{"key":"B76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"B77","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/bjh.12031","article-title":"Emerging pathogens and their implications for the blood supply and transfusion transmitted infections","volume":"159","author":"Dodd","year":"2012","journal-title":"Br J Haematol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.tmrv.2017.05.002","article-title":"Emerging infectious diseases and blood safety: modeling the transfusion-transmission risk","volume":"31","author":"Kiely","year":"2017","journal-title":"Transfus Med Rev"},{"key":"B79","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.mayocp.2013.03.014","article-title":"Herpes zoster eye complications: rates and trends","volume":"88","author":"Yawn","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"B80","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2450\/2017.0344-16","article-title":"Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA\/RNA: design, technologies, and future prospects for developing countries","volume":"15","author":"Drew","year":"2017","journal-title":"Blood Transfus"},{"key":"B81","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.hoc.2016.01.005","article-title":"Pathogen inactivation technologies: the advent of pathogen-reduced blood components to reduce blood safety risk","volume":"30","author":"Devine","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"B82","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3727\/096368910X539056","article-title":"Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation","volume":"20","author":"Stahle","year":"2011","journal-title":"Cell Transplant"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0153573","DOI":"10.1371\/journal.pone.0153573","article-title":"Solvent\/detergent virally inactivated serum eye drops restore healthy ocular epithelium in a rabbit model of dry-eye syndrome","volume":"11","author":"Tseng","year":"2016","journal-title":"PLoS One"},{"key":"B84","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s00417-004-1106-5","article-title":"An optimised protocol for the production of autologous serum eyedrops","volume":"243","author":"Liu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B85","volume-title":"Good Practice Guidelines for Blood Establishments and Hospital Blood Banks Required to Comply with EU Directive 2005\/62\/EC \u2013 Guide to the Preparation, Use and Quality Assurance of Blood Components. Recommendation No. R (95) 15","year":"2015"},{"key":"B86","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40123-017-0100-z","article-title":"Treatment of dry eye disease with autologous platelet-rich plasma: a prospective, interventional, non-randomized study","volume":"6","author":"Alio","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"B87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.transci.2016.01.022","article-title":"Quality standards, safety and efficacy of blood-derived serum eye drops: a review","volume":"54","author":"van der Meer","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"B88","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1097\/ICO.0b013e3180645cd7","article-title":"Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease","volume":"26","author":"Chiang","year":"2007","journal-title":"Cornea"},{"key":"B89","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/bjo.2003.026211","article-title":"Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease","volume":"88","author":"Noble","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ajo.2004.08.040","article-title":"The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study","volume":"139","author":"Kojima","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","article-title":"Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects","volume":"28","author":"Jeng","year":"2009","journal-title":"Cornea"},{"key":"B92","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1089\/jop.2012.0002","article-title":"Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease","volume":"28","author":"Na","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"B93","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00417-014-2599-1","article-title":"The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study","volume":"252","author":"Celebi","year":"2014","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.eye.6703079","article-title":"Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect","volume":"23","author":"Chiang","year":"2009","journal-title":"Eye (Lond)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/02713680601147690","article-title":"Albumin rescues ocular epithelial cells from cell death in dry eye","volume":"32","author":"Higuchi","year":"2007","journal-title":"Curr Eye Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/bjo.87.10.1279","article-title":"Albumin as a tear supplement in the treatment of severe dry eye","volume":"87","author":"Shimmura","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/ICU.0000000000000169","article-title":"Eye platelet-rich plasma in the treatment of ocular surface disorders","volume":"26","author":"Alio","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2174\/138920112800624355","article-title":"The role of \u201ceye platelet rich plasma (E-PRP)\u201d for wound healing in ophthalmology","volume":"13","author":"Alio","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/ICO.0000000000000016","article-title":"Restoration of human lacrimal function following platelet-rich plasma injection","volume":"33","author":"Avila","year":"2014","journal-title":"Cornea"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1097\/Ico.0000000000000489","article-title":"Preservation of biological activity of plasma and platelet-derived eye drops after their different time and temperature conditions of storage","volume":"34","author":"Anitua","year":"2015","journal-title":"Cornea"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1097\/ICO.0b013e31820d86d6","article-title":"Efficacy of plasma rich in growth factors for the treatment of dry eye","volume":"30","author":"Lopez-Plandolit","year":"2011","journal-title":"Cornea"},{"key":"B102","first-page":"529","article-title":"Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants","volume":"14","author":"Anitua","year":"1999","journal-title":"Int J Oral Maxillofac Implants"},{"key":"B103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.transci.2016.01.023","article-title":"Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress","volume":"54","author":"Seghatchian","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/eye.2017.118","article-title":"Fingerprick autologous blood: a novel treatment for dry eye syndrome","volume":"31","author":"Than","year":"2017","journal-title":"Eye (Lond)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.transci.2015.05.016","article-title":"Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: seeing is believing","volume":"53","author":"Tseng","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"B106","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.biomaterials.2017.07.018","article-title":"Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson\u2019s disease","volume":"142","author":"Chou","year":"2017","journal-title":"Biomaterials"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2018.00033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T13:32:47Z","timestamp":1719840767000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2018.00033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,23]]},"references-count":106,"alternative-id":["10.3389\/fmed.2018.00033"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2018.00033","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,23]]},"article-number":"33"}}